Coronavirus Files: CDC shrinks quarantines; vaccines imminent; race impacts COVID-19 testing, vaccination and distance learning

Author(s)
Published on
December 8, 2020

Image

Since April, The Center for Health Journalism has been publishing a special newsletter geared to journalists as they report on one of the biggest and most complex stories of our times. Each Monday, while the pandemic runs its course, The Coronavirus Files will provide tips and resources and highlight exemplary work to help you with your coverage. This week, The Center for Health Journalism’s Coronavirus Files Monday newsletter is curated and reported by science wrier Amber Dance, Ph.D. Have a suggestion or a request? Write us at editor@centerforhealthjournalism.org.
 

CDC shortens recommended quarantine times

For months, 14 days has been the magic number, but on Dec. 2 the CDC announced that people exposed to someone with COVID-19, but lacking any symptoms themselves, could get back to their normal activities in 10 days. If they also test negative, they can stop quarantine after seven days.

The new guidelines reflect the fact that symptoms and infectiousness usually peak within five days. The agency hopes more people will quarantine if the duration is shorter. But 14 days remains the gold standard, and there’s a small risk — about 1% — that someone who leaves quarantine after 10 days could still spread the virus, reports Damian McNamara at MedScape.

The CDC has also said that essential workers who’ve been exposed to the virus may remain at work instead of quarantining, as a “last resort and only in limited circumstances.” In addition, the CDC recommended that people who insist on traveling for the holidays should be tested one to three days before they go, and within three to five days of return.

Pfizer and Moderna shots poised for deployment, while questions swirl about AstraZeneca’s

Pfizer’s shot got the green light from the U.K. on Dec. 2, prompting Benjamin Mueller of The New York Times to ask why that nation got there first. In the U.S., the FDA will convene its expert panel on Dec. 10, and is slower in part because it’s one of few national agencies that analyzes raw trial data, rather than relying on a company’s own analysis. Moderna is following close on Pfizer’s heels, with its own FDA review set for Dec. 17.

Meanwhile, scientists are puzzled by the results of AstraZeneca’s trial, writes Ewen Callaway in Nature. Among people who received two full doses, the vaccine was 62% effective. But that rose to 90% in a group of subjects who — by mistake — received just a half-dose in the first shot. Bloomberg reports that the company will probably conduct another trial aiming to confirm the 90% efficacy, which may slow U.S. approval.

Vice President Mike Pence told governors to expect vaccine distribution as early as next week, with more than 20 million people potentially vaccinated by year’s end, although setbacks could shrink that figure. The CDC’s Advisory Committee on Immunization Practices recommended that health care workers and residents of long-term care facilities be first in line. That’s despite questions about how effective the shot will be in nursing home residents, Melissa Healy reports in the Los Angeles Times. Distribution plans are ultimately in the hands of states and local governments.

Vaccines are expected to be available to the majority of Americans by spring or summer. But that projection leaves out children and pregnant people. Trials thus far have been limited to the non-pregnant and non-breastfeeding, even though pregnancy increases risk for COVID-related complications, reports Chelsea Cirruzzo at The Lily. Pfizer and Johnson & Johnson have begun vaccine trials in kids as young as 12, and Moderna just announced it would do the same. In The Washington Post, Meryl Kornfield reports that kids might not get immunized before the start of the 2021 school year.

Race, poverty influence pandemic consequences

Meanwhile, students in elementary and middle school are already falling behind in math, according to a recent report. For students of color, reading is also a growing area of concern.

President-Elect Joe Biden’s team plans to address the racial disparities that exacerbate the crisis for some populations, reports AP’s Carla K. Johnson, who interviewed a top Biden adviser from Yale’s medical school. “This is a unified voice, across the entire transition,” said Marcella Nunez-Smith in the interview.

The AP reports that people who can’t afford $150 or more for a COVID-19 test may be forced to wait for hours for a free test, then days for the results, forcing them to take time off work and deepening their economic distress. And given a long history of medical mistreatment and racism, some Black people are particularly wary of getting a vaccine. Nunez-Smith said testing and vaccination programs must address fairness and equity. 

What we’re reading

 Resources & events 

Visual Risk Communication: Evidence-Based Tips for Crafting Powerful Visual Messages is a tips-packed blog post on Lifeology by Alice Fleerackers